Drug Type Bispecific antibody |
Synonyms zeripatamig |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD47 inhibitors(Cluster of differentiation 47 inhibitors) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization- |
Active Organization- |
Inactive Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |